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Background: The clinical stage of the disease at diagnosis often determines the prognosis and survival rate of a
patient with pancreatic cancer. Early symptoms of pancreatic cancer are often not obvious on imaging (ultrasound,
computed tomography (CT), and so on), and when patients present with weight loss, jaundice and abdominal pain
and other symptoms, they are usually already in the advanced stages of pancreatic cancer. However, the examination
of combined tumor markers might improve their sensitivity or specificity in aiding diagnosis.
Methods: Twelve tumor markers including AFP, CEA, NSE, CA125, CA15-3, CA242, CA19-9, PSA, f-PSA, FER, β-HCG and
HGH were measured by the protein biochip detection in serum in 235 pancreatic cancer patients, 230 benign
pancreatic disease patients and 240 healthy people.
Results: Positive detection rates of tumor markers were: CA19-9 (49.3%), CA125 (45.1%), FER (44.2%), CA242
(42.5%), CEA (38.6%), CA15-3 (36.7%), β-HCG (29.6%), AFP (24.5%), NSE (18.2%), PSA (19.5%), f-PSA (9.4%) and HGH
(8.7%) respectively. There was significant difference in CA19-9, NSE, CEA, CA242 and CA125 by multi-tumor marker
protein biochip detection among patients with cancer, benign disease and healthy people (P <0.05). The positive
rate of 5 tumor markers was 94.9%, and this was much higher than that of any single marker.
Conclusion: The detection of CA19-9, NSE, CEA, CA242 and CA125 in the multi-tumor marker protein biochip
system is helpful in the diagnosis of pancreatic cancer.
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Early detection of cancer has improved the survival of
patients with many types of cancer and is critical for
future improvements in effectively treating the disease
[1]. The detection of serum tumor markers is an effect-
ive and non-invasive diagnostic or prognostic tool for
pancreatic cancer. The two major reasons that most
tumor markers are not used for tumor screening are
their low sensitivity and specificity, resulting in low
detection rates and unacceptable false-positive diagnoses
[2]. The examination of combined tumor markers might
improve the sensitivity or specificity [3].
The purpose of this study was to evaluate the diag-
nostic value of multi-tumor marker protein biochip
detection for pancreatic cancer. This protein biochip* Correspondence: dufutian666@sina.com
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including cancer antigen (CA)125, CA15-3, CA19-9,
CA242, carcinoembryonic antigen (CEA), R-fetoprotein
(AFP), prostate specific antigen (PSA), free-prostate
specific antigen (f-PSA), human growth hormone (HGH)‚
β-human chorionic gonadotropin (β-HCG), neuron-
specific enolase (NSE) and ferritin (FER), in the serum
and was tested in clinically confirmed cancer patients and
apparently healthy individuals. The value of this biochip in
cancer screening of apparently healthy populations and in
cancer patients is discussed.Methods
Patients and serum samples
From June 2012 to October 2013, 235 patients (150 men
and 85 women, median age 61 years, range 20 to 78
years) with pancreatic cancer were included in the study
group. One hundred and fifteen patients were treated
with pancreaticoduodenectomy or distal pancreatectomyThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 The workflow of the chip detection system.
Table 2 Positive rate of pancreatic cancer versus benign
pancreatic disease
Pancreatic cancer Benign pancreatic disease
(n =235) (n =230)
CA19-9 (U/ml) 49.3% 14.2%
CA125 (U/ml) 47.3% 13.6%
FER (ng/ml) 43.2% 49.2%
CA242 (U/ml) 42.7% 23.6%
CEA (ng/ml) 36.4% 14.8%
CA15-3 (U/ml) 28.7% 0
β-HCG (mIU/ml) 25.5% 0
AFP (ng/ml) 20.4% 0
NSE (ng/ml) 18.9% 0
PSA (ng/ml) 13.5% 0
f-PSA (ng/ml) 14.1% 0
Source of the curve: —— The combined five markers, − − - CEA, · · · CA125, · · ·
CA15-3, —— Reference line.
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According to the TNM Classification, fifth edition [4],
there were 22 stage I patients, 140 stage II patients and 73
stage III patients. The location of tumor was divided into
head (48 cases), body/tail (146 cases) and the whole
pancreas (59 cases). The tumor size was divided into equal
to (12 cases) and smaller than 5 cm (154 cases), or larger
than 5 cm (69 cases) in diameter. All diagnoses were
confirmed by histology of postoperative or cytology of
intraoperative biopsy examination. In addition, there
were 230 benign pancreatic diseases (100 chronic pan-
creatitis and 130 benign adenomas, including 61 men
and 39 women, age ranging from 20 to 82 years), and
240 blood donors and other volunteers known to be in
good health.Table 1 Twelve (C-12) protein biochip test results of healthy,
Healthy Benign pancr
(n =240) (n =230)
CA19-9 (U/ml) 4.5 ± 2. 8 16.4 ± 19.2
CA125 (U/ml) 2.9 ± 2. 6 18.9 ± 28.7
FER (ng/ml) 118.9 ± 62.6 320.9 ± 285
CA242 (U/ml) 2.3 ± 0.8 9.3 ± 14.7
CEA (ng/ml) 1.1 ± 0.5 1.87 ± 2.3
CA15-3 (U/ml) 5.1 ± 4.2 13.4 ± 6.8
β-HCG (mIU/ml) 0.1 ± 0.1 0.5 ± 0.4
AFP (ng/ml) 3.3 ± 2.4 1.6 ± 1.8
NSE (ng/ml) 1.3 ± 0.8 2.1 ± 2.3
PSA (ng/ml) 0.3 ± 0.2 0.6 ± 0.5
f-PSA (ng/ml) 0.1 ± 0.1 0.2 ± 0.2
HGH (ng/ml) 0.1 ± 0.2 0.8 ± 0.7Sample preparation
Horseradish peroxidase (HRP) and chemiluminescence sub
strates (SuperSignal Femto maximum sensitivity) were
purchased from Pierce (Rockford, IL, USA). Antigens
and antibodies were produced in our laboratory. Anti-
body conjugation was done according to Nakane and
Kawaio’s article [5].
Sample measurement
One point five microliters of each of the 12 capture anti-
bodies, with an average concentration of 1 mg/mL, were
arrayed in duplicates on a 1 × 1 cm nitrocellulose mem-
brane. The array consisted of a 5 × 5 matrix with 12 pairs
of antibody spots and 1 blank spot as control. After spot-
ting, the membrane was mounted with a plastic mold andbenign pancreatic and pancreatic cancer subjects
eatic Pancreatic cancer P-value
(n =235) (SNK method)
203.8 ± 296.5 0. 0008
174.6 ± 266.2 0. 0016
373.8 ± 385.5 0. 5579
130.5 ± 150.5 0. 0035
13.5 ± 27.1 0. 0392
79.4 ± 82.3 0. 0584
8.96 ± 12.8 0. 0694
14.5 ± 36.8 0. 0568
7.9 ± 12.8 0. 0179
1.5 ± 2.38 0. 0575
0.6 ± 0.6 0. 1046
4.5 ± 4.8 0. 0564
Figure 2 ROC curve.
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with 100 μL of serum, rinsed and washed with TBST (0.1
mol Tris-HCl, 8.5 g NaCl, 1 mL Tween 20, pH 7.6). The
chip was then incubated with 100 μL of HRP-labeled
antibodies for 30 minutes at 37°C and again rinsed and
washed with TBST. Chemiluminescence substrates were
added for 1 minute. Light signals were captured with the
self-built chip reader based on a CCD camera and con-
trolled with a computer system using self-developed
software. The workflow of the chip detection system is
shown in Figure 1.Statistical analysis
Due to non-normal distribution of the raw data, a loga-
rithmic transformation was needed. Data collected were
subjected to appropriate transformation (square root)
before analysis of variance was performed and means wereTable 3 The relationship between the serum markers and the
Group Number CEA
value (ng/ml) P-value
Tumor location head 48 20.6 ± 42.6
Body/tail 146 28.0 ± 33.1
Whole 59 74.9 ± 232.1 P >0.5
Tumor size
≤ 5 cm 166 23.7 ± 39.1
> 5 cm 69 23.9 ± 36.3 P >0.5
TNM stage
I 22 14.1 ± 16.6
II 140 12.7 ± 28.3
III 73 90.3 ± 212.8 P <0.5separated by SAS-SNK (P <0.05) test (SAS Institute, Cary,
NC, USA; 1989).
Results
Positive detection rates of tumor markers were: CA19-9
(49.3%), CA125 (45.1%), FER (44.2%), CA242 (42.5%), CEA
(38.6%), CA15-3 (36.7%), β-HCG (29.6%), AFP (24.5%),
NSE (18.2%), PSA (19.5%), f-PSA (9.4%) and HGH (8.7%)
respectively (Table 1).
There was significant difference in CA19-9, NSE,
CEA, CA242, CA125 by multi-tumor marker protein
biochip detection among patients with cancer, benign
disease and apparently healthy people (P <0.05). We
took the normal value of tumor marker serum level as
cut-off value to determine the negative or positive likeli-
hood of pancreatic cancer. The positive rate of 5 tumor
markers was 94.9%, which was much higher than that of
any single marker (Table 2). Figure 2 shows the receiver
operating characteristic (ROC) curves of the 5 markers.
The diagnostic performance of markers was ranked
according to the area under the curves.
It was noticed that the CA19-9 levels were significantly
higher in patients with cancer of the pancreatic body and
tail than of the pancreatic head (P =0.047). There was no
correlation of serum CEA and CA242 with tumor location
(P >0.05). The serum levels of CEA, CA19-9, and CA242
were obviously higher in stage III patients than in stages I
and II (P <0.05). However, the serum levels of CEA,
CA19-9 and CA242 in patients with pancreatic cancer
were not affected by the tumor size (P >0.05) (Table 3).
Discussion
Due to their limited specificity, the measurement of a
single tumor marker is usually not sufficient to diagnose
cancer. Impressive integration efforts are demonstrated
by the ability to perform on-chip trypsin digestion, sep-
aration and injection into a mass spectrometer with a
single device [6]. Elevated levels of the proteins CEA,location, size, and TNM stage of pancreatic cancer
CA19-9 CA242
value (ng/ml) P-value value (ng/ml) P-value
756.6 ± 1,228.2 58.3 ± 55.3
2,902.5 ± 3,308.3 76.1 ± 72.1
1,517.3 ± 2,928.6 P <0.5 72.6 ± 60.3 P >0.5
1,113.4 ± 2,660.4 45.2 ± 48.1
1,258.9 ± 5,002.3 P >0.5 59.1 ± 60.3 P >0.5
1,126.6 ± 1,425.9 57.6 ± 54.4
845.0 ± 2,000.7 53.9 ± 52.1
2,976.6 ± 3,513.2 P <0.5 97.6 ± 67.1 P <0.5
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associated with lung, pancreatic, breast, colorectal, and
other types of cancer [7-10]. Several studies have shown
that the measurement of panels of tumor markers can
improve their diagnostic value [5-8]. In previous reports,
the levels of serum CEA, CA19-9 and CA242 in patients
with pancreatic cancer were higher than those of other
malignant diseases and benign pancreatic diseases [7,11].
Here, we found that the combination of CEA and CA242
could increase the specificity to 94.9% in the diagnosis of
pancreatic cancer. This is important in helping to differen-
tiate pancreatic cancer from other malignancies and
benign pancreatic diseases.
Conclusion
The biosensor system described here is suitable for
the measurement of a wide range of biomarkers. We
compared the serum levels of CA19-9, CA125, FER,
CA242, CEA, CA15-3, β-HCG, AFP, NSE, PSA, f-PSA
and HGH associated with pancreatic cancer, and found
that simultaneous analysis of them was important for the
diagnosis of pancreatic cancer. The detection of CA19-9,
NSE, CEA, CA242 and CA125 in the multi-tumor
markers protein biochip system is helpful in the diagnosis
of pancreatic cancer.
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